scholarly journals Pitavastatin, an HMG-CoA Reductase Inhibitor, Exerts eNOS-Independent Protective Actions Against Angiotensin II–Induced Cardiovascular Remodeling and Renal Insufficiency

2008 ◽  
Vol 102 (1) ◽  
pp. 68-76 ◽  
Author(s):  
Shusuke Yagi ◽  
Ken-ichi Aihara ◽  
Yasumasa Ikeda ◽  
Yuka Sumitomo ◽  
Sumiko Yoshida ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Renal Insufficiency ◽  
Reductase Inhibitor ◽  
Hmg Coa Reductase ◽  
Cardiovascular Remodeling ◽  
Protective Actions ◽  
Hmg Coa Reductase Inhibitor ◽  
Coa Reductase

Abstract 180: Synergistic Salutary Effects of HMG-CoA Reductase Inhibitor and Angiotensin II Receptor Blocker on Load-induced Heart Failure

2014 ◽  
Vol 115 (suppl_1) ◽  
Author(s):  
Yasuhiro Maejima ◽  
Mitsuaki Isobe
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
Reductase Inhibitor ◽  
Neonatal Rat ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Hmg Coa Reductase ◽  
Hmg Coa Reductase Inhibitor ◽  
Coa Reductase

We have shown previously that combined HMG-CoA reductase inhibitor (statin) and angiotensin II receptor blocker (ARB) therapy significantly improves both symptoms and left ventricular (LV) function over time in patients with heart failure (HF) by a clinical study [ HF-COSTAR Trial]. We elucidated the mechanisms of combination therapy with the ARB (losartan, LOS) and long-acting and statin (simvastatin, SIM) for the treatment of load-induced heart failure. Salt-loaded Dahl salt-sensitive (DS) rats were treated with vehicle, LOS (5mg/kg/day), SIM (2mg/kg/day) and LOS + SIM for 16 weeks. LOS and SIM in combination improved LV dysfunction (ΔLV fractional shortening; LOS = 60%, SIM = 42%, LOS + SIM = 24%, p <0.05), limited LV hypertrophy (ΔLV septal thickness; LOS = −21%, SIM = −18%, LOS + SIM = −13%, p <0.05) and reduced cardiac fibrosis (ΔLV collagen density; LOS = −26%, SIM = −16%, LOS + SIM = −28%, p <0.05) more than LOS or SIM alone. Both Rho and matrix metalloprotease-9 (MMP-9) activity in LV tissue were increased in untreated DS rats, and LOS and SIM in combination decreased these changes more than did LOS and SIM monotherapies. We confirmed that the plasma level of Exp-3174 (E3174), a LOS metabolite and a potent inverse agonist of angiotensin II receptor type 1, was higher in rats treated with LOS and SIM in combination than in those treated with LOS alone (E3174/LOS ratio; LOS = 2.6 ± 0.3 vs. LOS + SIM = 3.2 ± 0.2, p <0.05). Next, to mimic the response of volume-overload heart failure in vitro , cultured neonatal rat cardiomyocytes (CMs) were cyclically stretched. Stretch-induced increased CM hypertrophy was suppressed by pretreatment with both SIM and E3174 more than by pretreatment with LOS, E3174, SIM, or LOS and SIM in combination. Mechanical stretch also induced activation of extracellular signal regulated kinase (ERK) and the stretch-induced ERK activation of CMs was also significantly suppressed by SIM + E3174. In conclusion, LOS and SIM had beneficial myocardial effects in rats with salt-sensitive hypertension, partly through promoting the accumulation of plasma E3174. SIM enhanced the myocardial protective effects of LOS through suppression of Rho and MMP-9 activity. Thus, a combination of ARB with statin has a promising potential as a therapeutic strategy for HF.

scholarly journals Combination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomy

2012 ◽  
Vol 27 (7) ◽  
pp. 2720-2733 ◽  
Author(s):  
Alejandro Álvarez-Prats ◽  
Octavio Hernández-Perera ◽  
Pilar Díaz-Herrera ◽  
Álvaro C. Ucero ◽  
Aránzazu Anabitarte-Prieto ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Combination Therapy ◽  
Reductase Inhibitor ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Hmg Coa Reductase ◽  
Subtotal Nephrectomy ◽  
Hmg Coa Reductase Inhibitor ◽  
Coa Reductase

scholarly journals Synergistic effects of HMG ‐CoA reductase inhibitor and angiotensin II receptor blocker on load‐induced heart failure

FEBS Open Bio ◽  
2018 ◽  
Vol 8 (5) ◽  
pp. 799-816 ◽  
Author(s):  
Yusuke Ito ◽  
Yasuhiro Maejima ◽  
Natsuko Tamura ◽  
Yuka Shiheido‐Watanabe ◽  
Masanori Konishi ◽  
...  
Keyword(s):  
Heart Failure ◽  
Angiotensin Ii ◽  
Reductase Inhibitor ◽  
Synergistic Effects ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Hmg Coa Reductase ◽  
Hmg Coa Reductase Inhibitor ◽  
Coa Reductase

HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1

Life Sciences ◽  
2006 ◽  
Vol 79 (14) ◽  
pp. 1380-1390 ◽  
Author(s):  
Kino Morikawa-Futamatsu ◽  
Susumu Adachi ◽  
Yasuhiro Maejima ◽  
Mimi Tamamori-Adachi ◽  
Jun-ichi Suzuki ◽  
...  
Keyword(s):  
Angiotensin Ii ◽  
Cardiac Hypertrophy ◽  
Cyclin D1 ◽  
Reductase Inhibitor ◽  
Rho Kinase ◽  
Hmg Coa Reductase ◽  
Hmg Coa Reductase Inhibitor ◽  
Coa Reductase

Effects of an HMG-CoA reductase inhibitor, simvastatin, on human myeloma cells

2004 ◽  
Author(s):  
Takemi Otsuki ◽  
Haruko Sakaguchi ◽  
Tamayo Hatayama ◽  
Tomohiro Fujii ◽  
Takayuki Tsujioka ◽  
...  
Keyword(s):  
Reductase Inhibitor ◽  
Hmg Coa Reductase ◽  
Myeloma Cells ◽  
Hmg Coa Reductase Inhibitor ◽  
Coa Reductase ◽  
Human Myeloma Cells
Sign in / Sign up

Export Citation Format

Share Document